Detalhe da pesquisa
1.
Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
Ann Hematol
; 101(12): 2711-2717, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36271935
2.
Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study.
Ther Adv Hematol
; 13: 20406207221090150, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35646300